Fundamental Analysis of Bellerophon Therapeutics Inc - Growth / Value Index
BLPH - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 28.86 suggesting that it is very expensive
Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 79.36 | % | ||
Price to Book | 28.86 | 0 | 0 % | 0.185 |
Price to Sales | 30.61 | 0 | 0 % | |
Enterprise Value to EBITDA Multiple | -0.0296 | 0 | 0 % |
BLPH - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Return On Equity of 36.36%
During the past twelve months, the company has given a strong Return On Asset of 20.62%
During the past twelve months, the company has given a strong Net Margin of 38.56%
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Poor Score of 29.46
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Assets
EPS decline for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 36.36 | % | -51.60 | |
Return On Asset | 20.62 | 0 | 0 % | -38.58 |
Net Profit Margin | 38.56 | -164.06 | 53.34 % | 0 |
Operating Profit Margin | -411.67 | -195.67 | 50.70 % | 0 |
EBITDA Margin | -412.04 | -163.95 | 58.69 % | 0 |
Highlights
Market Cap | 688695 |
Enterprise Value | 688695 |
Price/Book TTM | 28.86 |
Outstanding Share | 12232.60 K |
Float/ Outstanding Share | 83.41% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | |
Peter Lynch Ratio | 0 |
Piotroski F Score | 2.00 |
Altman Z Score | |
Sloan Ratio | |
Peter Lynch Fair Value | 0.0139 |
BLPH - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 11.54
Quarterly sales in last 5 Quarter is trending down
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 5640.00 K | 0 % | % |
Gross Profit | 5640.00 K | % | % |
EBITDA | -23239.00 K | 58.69 % | 58.74 % |
Net Profit | 2175.00 K | 53.34 % | 62.61 % |
EPS | 0.0007 | 100.00 % | NA |
BLPH - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0 | 0 % | 0 |
Cash Ratio | 0 | 0 % | |
Quick Ratio | 0 | 0 % | 3.96 |
Shareholders Equity | 0 | 0 % | |
Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Bellerophon Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Bellerophon Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Bellerophon Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Bellerophon Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)